Log In
BCIQ
Print this Print this
 

BMB-D001

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionRecombinant adeno-associated virus serotype 9 (rAAV9) vector delivering a shortened, but functional copy of the dystrophin gene
Molecular Target Dystrophin
Mechanism of Action 
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard IndicationMuscular dystrophy
Indication DetailsTreat Duchenne muscular dystrophy (DMD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$645.0M

$150.0M

$495.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/01/2016

$645.0M

$150.0M

$495.0M

Get a free BioCentury trial today